Both trials met their co-primary endpoints, demonstrating significant improvements in nasal polyp scores and nasal obstruction over 52 weeks compared to the placebo, according to an Oct. 14 news release from the company.
The condition, CRSwNP, causes significant symptoms including nasal obstruction and loss of smell, with 40% of cases being uncontrolled.
Depemokimab targets interleukin-5, a key cytokine linked to type 2 inflammation, which is prevalent in nasal polyp tissue.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.